Showing 1 - 5 results of 5 for search 'Pouria Basiri', query time: 0.03s Refine Results
  1. 1
    A Novel Case of Neglected Monteggia Fracture Dislocation

    A Novel Case of Neglected Monteggia Fracture Dislocation by Arvin Najafi, Pouria Basiri, Salman Azarsina, Mohamad Sajad Mirhoseini, Ehsan Seif

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial

    Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial by Mohammadreza Ahi, Ramin Hamidi Farahani, Pouria Basiri, Ahmad Karimi Rahjerdi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Fatemeh Gholami, Milad Moradi, Farzad Ghafoori Naeeni, Kosar Naderi Saffar, Soheil Ghasemi, Babak Barati, Sohrab Moradi, Arina Monazah, Fatemeh Pouranvari, Mohsen Forooghizadeh

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial

    Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial by Masoud Solaymani-Dodaran, Pouria Basiri, Milad Moradi, Kimiya Gohari, Ali Sheidaei, Mohammadreza Ahi, Farzad Ghafoori Naeeni, Akram Ansarifar, Zahra Rahimi, Fatemeh Gholami, Ahmad Karimi Rahjerdi, Ramin Hamidi Farahani, Kosar Naderi saffar, Soheil Ghasemi, Ali Shooshtari, Mohsen Honari, Ali Mozafari, Samane Khodaverdloo, Mohsen Forooghizadeh

    Published 2023-07-01
    Get full text
    Article
  4. 4
    Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

    Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years by Fatemeh Gholami, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, Mohammadreza Ahi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Akram Ansarifar, Pouria Basiri, Milad Moradi, Arash Jahangiri, Kosar Naderi, Soheil Ghasemi, Pezhman Khatami, Mohsen Honari, Samane Khodaverdloo, Mohammad Shooshtari, Hajar Mehr Azin, Sohrab Moradi, Batool Shafaghi, Hossein Allahyari, Arina Monazah, Ali Khodaei Poor, Zahra Taghva, Hooman Bakhshande, Mohammad Karimi Nia, Masoud Solaymani Dodaran, Mohsen Forooghizade

    Published 2023-02-01
    Get full text
    Article
  5. 5
    Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial

    Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial... by Akram Ansarifar, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, Mohammadreza Ahi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Fatemeh Gholami, Pouria Basiri, Milad Moradi, Arash Jahangiri, Kosar Naderi, Soheil Ghasemi, Pezhman Khatami, Mohsen Honari, Samane Khodaverdloo, Mohammad Shooshtari, Hajar Mehr Azin, Sohrab Moradi, Batool Shafaghi, Hossein Allahyari, Arina Monazah, Ali Khodaei Poor, Hooman Bakhshande, Zahra Taghva, Mohammad Karimi Nia, Masoud Solaymani Dodaran, Mohsen Foroughizadeh

    Published 2023-12-01
    Get full text
    Article

Search Tools: